Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients

Schulz, Heiko; Schmoeckel, Elisa; Kühn, Christina; Hofmann, Simone; Mayr, Doris; Mahner, Sven; Jeschke, Udo

doi:10.3390/ijms18061230

Cited by 36 publications

(62 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It could regulate apoptosis and cell differentiation, bind with CD45, CD3 and CD4 to inhibit CD45 protein phosphatase activity and lymphocyte-activated enzyme dephosphorylation [25]. Studies confirmed that Gal-1 was closely related with tumor development, metastasis, invasion and malignancy, such as gastric cancer [26], ovarian cancer [27], and pancreatic cancer [28]. In this study, our data indicated that Gal1 could promote CRC cells proliferation, migration and invasion.…”

Section: Discussionsupporting

confidence: 54%

CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis

et al. 2020

View full text Add to dashboard Cite

CHIP and Galectin-1 are associated with the development of metastasis in cancer. However, the precise roles of CHIP or Gal1 in colorectal cancer are uncertain. Here, our study explored the relationship and clinical significance of CHIP or Gal1 in CRC. CHIP or Gal1 expression was significantly decreased or up-regulated in CRC compared with adjacent noncancerous tissues by immunohistochemistry on a CRC tissue microarray, respectively. Low CHIP or high Gal1 expression significantly correlated with clinicopathological characteristics in patients, as well as with shorter overall survival. Multivariate Cox regression analysis revealed that CHIP or Gal1 expression was an independent prognostic factor for CRC patients. Moreover, CHIP associated with Gal1 has a synergistic effect on the prediction of CRC prognosis. In vitro and vivo, high CHIP or low Gal1 expression inhibit CRC growth or metastasis. Our results found that CHIP could degradate Gal1 by ubiquitination. In summary, CHIP could inhibit CRC growth or metastasis through promoting Gal1 ubiquitination and degradation by proteasome. CHIP and Gal1 expressions are novel candidate prognostic markers in CRC. A combined effect of CHIP and Gal1 as efficient prognostic indicators was found for the first time.

show abstract

Section: Discussionsupporting

confidence: 54%

CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Galectin-7 is well known as a p53 inducible protein. In other cancer types, including breast and ovarian, galectin-7 expression is elevated due to a mutation in the p53 gene (17,30). In breast cancer, this mutant p53 elevates galectin-7 via nuclear factor-κB and tumor necrosis factor α, without inducing apoptosis (30).…”

Section: Discussionmentioning

confidence: 99%

“…The role of galectin-7 in cancer can be pro-or anti-tumor: In breast cancer, galectin-7 is pro-tumor, enhancing spontaneous metastatic capability and protecting cancer cells from apoptosis (16). Galectin-7 is a negative prognostic marker for ovarian cancer (17) and renal clear-cell carcinoma (18). Conversely, galectin-7 may exhibit anti-tumor properties in other types of cancer; for example, it is absent in prostate cancer cells (19), reduced in gastric cancer (20) and causes prostate and DLD-1 colon cancer cells to have greater sensitivity to apoptosis (19,21).…”

Section: Introductionmentioning

confidence: 99%

Galectin‑7 is elevated in endometrioid (type I) endometrial cancer and promotes cell migration

et al. 2018

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most commonly diagnosed gynecological malignancy in Australian women. Notably, its incidence and mortality rate is increasing. Despite this, there are limited treatment options for EC. Galectin-7 regulates tumorigenesis in numerous epithelial cancer types, but the role of galectin-7 has not been investigated in EC. It was hypothesized that galectin-7 expression would be altered in EC and contribute to the development of EC. Galectin-7 levels in EC and benign endometrium were quantified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and ELISA. The effect of recombinant galectin-7 (1 µg/ml) on cell adhesion, proliferation, apoptosis (xCELLigence and flow cytometry), migration (wound healing assay) and gene expression (RT-qPCR) was investigated using three human EC cell lines (Ishikawa, HEC1A and AN3CA). Galectin-7 gene and protein expression was significantly elevated in Grade 3 EC, compared with benign tissues. Galectin-7 was almost undetectable in Ishikawa and AN3CA cells, but highly expressed by HEC1A cells. Recombinant galectin-7 had no significant effect on cell proliferation or apoptosis in any cell line, but significantly reduced cell adhesion in Ishikawa (at 4 and 6 h) and AN3CA (at 2, 3, 4 and 6 h). Galectin-7 significantly promoted Ishikawa migration and significantly elevated collagen type IV α 1 chain and intercellular adhesion molecule 1 (ICAM1) gene expression during wound healing. The present study demonstrated that galectin-7 production increased in EC with increasing cancer grade; therefore, galectin-7 may promote the metastasis of EC by reducing cell-cell adhesion and enhancing cell migration.

show abstract

“…Indeed, galectin-7 has been proposed to serve as a marker in patients with certain type of cancer. Interestingly, galectin-7 overexpression on tumour tissues could be correlated to patient survival notably in ovarian [ 114 ] or in cervical [ 59 , 115 ] carcinomas. Furthermore, galectin-7 expression has been associated with better survival after chemo- or radio-therapies [ 91 , 115 ] and has been proposed to serve as a predictive marker of chemo- and radio-therapy resistance [ 116 ].…”

Section: Galectin-7 and Carcinomasmentioning

confidence: 99%

Galectin-7 in Epithelial Homeostasis and Carcinomas

Advedissian

Deshayes

Viguier

2017

IJMS

View full text Add to dashboard Cite

Galectins are small unglycosylated soluble lectins distributed both inside and outside the cells. They share a conserved domain for the recognition of carbohydrates (CRD). Although galectins have a common affinity for β-galatosides, they exhibit different binding preferences for complex glycans. First described twenty years ago, galectin-7 is a prototypic galectin, with a single CRD, able to form divalent homodimers. This lectin, which is mainly expressed in stratified epithelia, has been described in epithelial tissues as being involved in apoptotic responses, in proliferation and differentiation but also in cell adhesion and migration. Most members of the galectins family have been associated with cancer biology. One of the main functions of galectins in cancer is their immunomodulating potential and anti-angiogenic activity. Indeed, galectin-1 and -3, are already targeted in clinical trials. Another relevant function of galectins in tumour progression is their ability to regulate cell migration and cell adhesion. Among these galectins, galectin-7 is abnormally expressed in various cancers, most prominently in carcinomas, and is involved in cancer progression and metastasis but its precise functions in tumour biology remain poorly understood. In this issue, we will focus on the physiological functions of galectin-7 in epithelia and present the alterations of galectin-7 expression in carcinomas with the aim to describe its possible functions in tumour progression.

show abstract

Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients

Cited by 36 publications

References 29 publications

CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis

CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis

Galectin‑7 is elevated in endometrioid (type I) endometrial cancer and promotes cell migration

Galectin-7 in Epithelial Homeostasis and Carcinomas

Contact Info

Product

Resources

About